GSK strengthens commitment to address major public health challenges in China

GSK China today announced it will form a strategic partnership with China Preventive Medicine Association (CPMA) under the guidance of National Health and Family Planning Commission of China (NHFPC). Within a three-year strategic collaboration framework, GSK China and CPMA will work closely together to address major public health challenges in China, including training to enhance capability building of prevenetion and vaccination workers in China, as well as disease awareness education to prevent major diseases such HIV, HBV and cervical cancer, to contribute to the speedy implementation of “Healthy China” Campaign.

Recenly, the Chinese government issued new regulations on the administration of vaccines distribution to further improve the quality and safety of vaccination in the country. GSK China fully supports the implementation of the new regulations, and will work together with CMPA on disease prevention education, as well as training of prevention and vaccination workers in the network of Disease Control Centre of China (CDC) to further enhance their capabilities, aiming to play an active role in the continuous improvement of China's healthcare infrastructure. Over the next three years, the training programme under this partnership will cover over 4,000 primary prevention and vaccination workers across the country.

HIV, HBV and cervical cancer are all major public health threats in China. Cervical cancer is the second most common cancer in women aged between 15 to 44 years in China, with an estimated 130,000 new cases each year. Every year, China accounts for more than 28% of the world's cervical cancer cases. Reported by the National Health & Family Planning Commission (NHFPC), in 2014 alone, 104,000 new cases of HIV infection were reported in China, a 14.8% increase over previous year. Moreover, the percentage of patients 24 years and younger living with HIV has been on the rise year on year. Hepatitis B has been identified as a healthcare priority in China, with approximately 20 million sufferers across the country remaining untreated.

GSK Chief Executive Officer Sir Andrew Witty said, “GSK is committed to China, and we're focusing our commitment on the therapeutic areas where we can make a real difference for the patients and people of China. This means how we can best align our strategy to the social, economic and development needs of China and its people. I see the strategic partnership with CPMA as an opportunity for us to deliver on this promise.”

The collaboration of GSK and CPMA could be traced back to over 10 years ago, and both parties have established mutual respect and a win-win relationship. Recently, GSK worked closely with CPMA on the World Hepatitis Day public education campaign in 2015 and 2016, to contribute to the HBV prevention and treatment efforts led by the Chinese government.

As part of the 'in China, with China, for China' strategy, GSK China has already:

  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Formalised a partnership with Shanghai-based Desano Pharmaceuticals to locally manufacture the Active Pharmaceutical Ingredient for Tivicay (dolutegravir) in July 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.


GSK – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit

GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.

GSK enquiries:

Susan Song            (Shanghai)

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.